GB Sciences has officially acquired exclusive worldwide licensing on a new potential time-released cannabinoid medicine for neuropathic pain. The use of nanotechnology to help neuropathy patients find a more effective delivery of their medicine comes from a from researchers at the Universidad de Seville (“USE”), the Universidad de Cadiz (“UCA”), and the Centro de Investigación Biomédica en Red de Salud Mental (“CIBERSAM”).
“GB Sciences recognizes the ineffectiveness of current delivery methods for cannabis-based medicines (i.e., smoking, vaping, sublingual, and ingestion), and therefore licensed this innovative new cannabinoid nanotechnology from the University of Seville,” explained Dr. Andrea Small-Howard, Chief Science Officer.
Dr. Mercedes Fernández Arévalo and Dr. Lucía Martín Banderas (USE) are leaders in the development of nanotechnology delivery systems. These researchers, alongside Dr. Juan A. Micó and Dr. Esther Berrocoso (UCA and CIBERSAM), used nanotechnology to encapsulate the medicine with a polymeric matrix to obtain four key benefits.
This polymeric matrix helps patients:
-
Avoid digestion of active ingredients.
-
Target their absorption.
-
Prolong blood circulation.
-
Provide a slow and steady release of active molecules.
A study was published in Nanomedicine: Nanotechnology, Biology and Medicine late July of this year demonstrating the effect of the time-released cannabinoid medicine. Results showed that one dose of medicine relieved neuropathic pain in rats for a whopping eleven days. Neuropathic pain is a chronic condition that is resistant to opioids and other pharmaceuticals. If CBD could prove effective, patients could finally have relief from this condition.
“We are excited to bring this new technology to the US for further development, and for commercialization worldwide,” says John Poss, CEO and Co-Chairman of GB Sciences. “This time-released formulation could be a real game-changer in the effort to control chronic conditions such as neuropathic pain.”
